Coxibs and Cardiovascular Disease

N Engl J Med. 2004 Oct 21;351(17):1709-11. doi: 10.1056/NEJMp048288. Epub 2004 Oct 6.

MeSH terms

  • Adverse Drug Reaction Reporting Systems
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Cardiovascular Diseases / chemically induced*
  • Celecoxib
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / adverse effects*
  • Cyclooxygenase Inhibitors / pharmacology
  • Drug Approval*
  • Drug Industry
  • Epoprostenol / antagonists & inhibitors
  • Gastrointestinal Diseases / chemically induced
  • Humans
  • Isoenzymes / antagonists & inhibitors
  • Isoenzymes / metabolism
  • Isoxazoles / adverse effects
  • Lactones / adverse effects*
  • Lactones / pharmacology
  • Membrane Proteins
  • Naproxen / adverse effects
  • Prostaglandin-Endoperoxide Synthases / metabolism
  • Pyrazoles
  • Risk
  • Sulfonamides / adverse effects
  • Sulfonamides / pharmacology
  • Sulfones
  • Thromboxane A2 / biosynthesis
  • United States
  • United States Food and Drug Administration

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Isoxazoles
  • Lactones
  • Membrane Proteins
  • Pyrazoles
  • Sulfonamides
  • Sulfones
  • rofecoxib
  • valdecoxib
  • Thromboxane A2
  • Naproxen
  • Epoprostenol
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Celecoxib